Online inquiry

IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11488MR)

This product GTTS-WQ11488MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Colorectal Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11488MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9410MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ2966MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ6445MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ2210MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ9526MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ13986MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ5703MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ14728MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW